Navigation Links
New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
Date:6/3/2010

HACKENSACK, N.J., June 3 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 4 – 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma. These findings are only three of 16 studies that will be discussed by researchers from the John Theurer Cancer Center.  

"We are excited to present significant research findings, particularly in the area of hematological malignancies, as part of our continued commitment to advance cancer research," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, John Theurer Cancer Center. "The studies we will present at ASCO represent just a small sample of the work that we do to improve outcomes not just for our patients, but for the cancer community as a whole."

Research to be presented at ASCO by researchers at the John Theurer Cancer Center will showcase treatment advancements for cancers of the blood, including lymphoma and multiple myeloma. Poster presentation highlights in these areas include:  

Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) combination may help patients with relapsed indolent B-cell lymphoma. (Abstract number 8078; poster session, June 5, 8:00 a.m.12:00 p.m.)

'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
2. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand
4. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
9. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused on ... of tumor cells in the bloodstream, today announced that ... support application powered by CollabRx, Inc. , Available ... Therapy Finder will provide breast cancer patients and their ...
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... , , , ... MITI ) ("Micromet" or the "Company"), a biopharmaceutical company ... inflammation and autoimmune diseases, today announced the closing of ... common stock. Micromet also announced that the underwriters ...
... SHANGHAI, Aug. 4 /PRNewswire-Asia/ -- ... ShangPharma Corporation, announced,today that it has moved its drug ... ChemPartner will provide fully integrated,services in the areas of ... Members of the joint project team from both sides ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company ... today announced dosing of its first patient in a Phase 2 ... acute heart failure. , , The single-blind, placebo-controlled ... safety and tolerability of CD-NP when infused for up to 72 ...
Cached Biology Technology:Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 2Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 2Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 3
(Date:4/17/2014)... new early-warning signs of the potential loss of sight ... for the diagnosis and treatment of diabetic retinopathy, potentially ... "We had not expected to see such striking changes ... Elsner, professor and associate dean in the IU School ... set out to study the early signs, in volunteer ...
(Date:4/17/2014)... University of Texas Medical Branch at Galveston are ... with radiation for cervical cancer should begin colorectal ... The UTMB researchers, finding a high incidence of ... with radiation, offer new recommendations that the younger ... about eight years after their initial cervical cancer ...
(Date:4/17/2014)... way the immune system may fight cancers and viral ... cells to treat illness. , The research, in mice, ... "neighborhood police" specialized squads of defenders that patrol ... entire city, the body. , Scientists at Washington University ... the liver, skin and uterus each has dedicated immune ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Radiation therapy for cervical cancer increases risk for colorectal cancer 2Some immune cells defend only 1 organ 2
... are invading the Great Lakes and changing the ecology of ... the March issue of the Journal of Great Lakes Research ... species, their ability to wrest territory from native fish plays ... , In the study, McMaster's Sigal Balshine, an assistant professor ...
... University's Pratt School of Engineering have created a new ... the probe creates a picture of the whole heart ... to image a single heart cross section. , The ... the condition of the heart, but also for use ...
... the brain and, more specifically, how nerve cells form billions of ... a scientific mystery. , A team headed by Drs. Robin Hiesinger ... have unraveled a piece of that puzzle by finding a gene ... their work appears today in the journal Neuron. , "We were ...
Cached Biology News:Duke engineers develop new 3-D cardiac imaging probe 2
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... General description: The "egg crate" style ... any Costar flat bottom strips. Linkage: This ... created to easily match Cornings product number. ... under the old Sigma-Aldrich number (Z71,456-9) or ...
... This reagent is intended for use as ... MTF). Michels Transport Fluid is useful for ... lymph nodes) for immunofluorescence studies. Samples may ... days at room temperature. Michels Transport Fluid ...
... Two sizes available for use with 96- or 384-well ... 96 for ease of location on 96-tube plates ... the skirt of the plate* Efficient sealing is ... in conjunction with screw or clip-down hot lid thermal ...
Biology Products: